Bites by Tomodon dorsatus (serpentes, dipsadidae): Clinical and epidemiological study of 86 cases.

A total of 86 proven cases of Tomodon dorsatus bites admitted to Hospital Vital Brazil (HVB) of Butantan Institute, in São Paulo, Brazil, between 1945 and 2018, were retrospectively analyzed. The cases included were those in which the snake was brought to HVB and was correctly identified. Of the 86 cases of snake bites, it was possible to describe the sex of the snake in 52 cases; 31 (59.6%) snakes were male. Only 52 snakes out of 86 could be studied because of their preservation status. The length of snakes (snout-vent length) ranged from 180 to 770 mm. Of the 86 snakes, 72 could be distinguished as adults (n = 63, 87.5%) or juveniles (n = 9, 12.5%). Most bites occurred in the spring and summer seasons (n = 57, 66.3%) and during warmer periods of the day (n = 61, 72.6%), between 9 a.m. and 3 p.m. The mean (±standard deviation) age of the victims was 26.9 ±â€¯17.2 years, and 60 (69.8%) were men. Approximately 90% of the patients sought medical care within 6 h after the bite. Both upper (n = 45, 52.3%) and lower (n = 37, 43.0%) limbs were the most frequently bitten, particularly the feet and hands (n = 54, 62.8%). The local clinical manifestations were pain (n = 55, 64.0%), transitory bleeding (n = 23, 26.7%), erythema (n = 22, 25.6%), edema (n = 14, 16.3%), paresthesia (n = 9, 10.5%), and ecchymosis (n = 3, 3.5%). Only 10 (11.6%) patients reported non-specific systemic symptoms characterized by transient dizziness or mild headache, and 21 (24.4%) patients showed no evidence of envenomation. A 20 min whole blood clotting test was performed in 31 (36.0%) patients on admission and all of them had coagulable blood. Supportive treatment was offered to 38 (44.2%) patients, namely, antiseptic (n = 20, 23.3%), antihistamines (n = 12, 14.0%), and analgesics (n = 9, 10.5%). Four (4.7%) patients were inappropriately treated with Bothrops antivenom before their admission to HVB. No sequelae or relevant complications were observed in patients, and the prognosis was benign. Therefore, although T. dorsatus bites can cause mild local symptomatology, it is important that health professionals know how to make the correct diagnosis to avoid unnecessary use of antivenom.

Bites by Tomodon dorsatus (serpentes, dipsadidae): clinical and epidemiological study of 86 cases

A total of 86 proven cases ofTomodon dorsatusbites admitted to Hospital Vital Brazil (HVB) of ButantanInstitute, in São Paulo, Brazil, between 1945 and 2018, were retrospectively analyzed. The cases included werethose in which the snake was brought to HVB and was correctly identified. Of the 86 cases of snake bites, it waspossible to describe the sex of the snake in 52 cases; 31 (59.6%) snakes were male. Only 52 snakes out of 86could be studied because of their preservation status. The length of snakes (snout–vent length) ranged from 180to 770 mm. Of the 86 snakes, 72 could be distinguished as adults (n = 63, 87.5%) or juveniles (n = 9, 12.5%).Most bites occurred in the spring and summer seasons (n = 57, 66.3%) and during warmer periods of the day(n = 61, 72.6%), between 9A.M. and 3P.M. The mean ( ± standard deviation) age of the victims was 26.9 ± 17.2 years, and 60 (69.8%) were men.Approximately 90% of the patients sought medical care within 6 h after the bite. Both upper (n = 45, 52.3%)and lower (n = 37, 43.0%) limbs were the most frequently bitten, particularly the feet and hands (n = 54,62.8%). The local clinical manifestations were pain (n = 55, 64.0%), transitory bleeding (n = 23, 26.7%), er-ythema (n = 22, 25.6%), edema (n = 14, 16.3%), paresthesia (n = 9, 10.5%), and ecchymosis (n = 3, 3.5%).Only 10 (11.6%) patients reported non-specific systemic symptoms characterized by transient dizziness or mildheadache, and 21 (24.4%) patients showed no evidence of envenomation. A 20 min whole blood clotting test wasperformed in 31 (36.0%) patients on admission and all of them had coagulable blood. Supportive treatment wasoffered to 38 (44.2%) patients, namely, antiseptic (n = 20, 23.3%), antihistamines (n = 12, 14.0%), and an-algesics (n = 9, 10.5%). Four (4.7%) patients were inappropriately treated withBothropsantivenom before theiradmission to HVB. No sequelae or relevant complications were observed in patients, and the prognosis wasbenign. Therefore, althoughT. dorsatusbites can cause mild local symptomatology, it is important that healthprofessionals know how to make the correct diagnosis to avoid unnecessary use of antivenom.

Bites by Tomodon dorsatus (serpentes, dipsadidae): clinical and epidemiological study of 86 cases

A total of 86 proven cases ofTomodon dorsatusbites admitted to Hospital Vital Brazil (HVB) of ButantanInstitute, in São Paulo, Brazil, between 1945 and 2018, were retrospectively analyzed. The cases included werethose in which the snake was brought to HVB and was correctly identified. Of the 86 cases of snake bites, it waspossible to describe the sex of the snake in 52 cases; 31 (59.6%) snakes were male. Only 52 snakes out of 86could be studied because of their preservation status. The length of snakes (snout–vent length) ranged from 180to 770 mm. Of the 86 snakes, 72 could be distinguished as adults (n = 63, 87.5%) or juveniles (n = 9, 12.5%).Most bites occurred in the spring and summer seasons (n = 57, 66.3%) and during warmer periods of the day(n = 61, 72.6%), between 9A.M. and 3P.M. The mean ( ± standard deviation) age of the victims was 26.9 ± 17.2 years, and 60 (69.8%) were men.Approximately 90% of the patients sought medical care within 6 h after the bite. Both upper (n = 45, 52.3%)and lower (n = 37, 43.0%) limbs were the most frequently bitten, particularly the feet and hands (n = 54,62.8%). The local clinical manifestations were pain (n = 55, 64.0%), transitory bleeding (n = 23, 26.7%), er-ythema (n = 22, 25.6%), edema (n = 14, 16.3%), paresthesia (n = 9, 10.5%), and ecchymosis (n = 3, 3.5%).Only 10 (11.6%) patients reported non-specific systemic symptoms characterized by transient dizziness or mildheadache, and 21 (24.4%) patients showed no evidence of envenomation. A 20 min whole blood clotting test wasperformed in 31 (36.0%) patients on admission and all of them had coagulable blood. Supportive treatment wasoffered to 38 (44.2%) patients, namely, antiseptic (n = 20, 23.3%), antihistamines (n = 12, 14.0%), and an-algesics (n = 9, 10.5%). Four (4.7%) patients were inappropriately treated withBothropsantivenom before theiradmission to HVB. No sequelae or relevant complications were observed in patients, and the prognosis wasbenign. Therefore, althoughT. dorsatusbites can cause mild local symptomatology, it is important that healthprofessionals know how to make the correct diagnosis to avoid unnecessary use of antivenom.

A new tick Kunitz type inhibitor, Amblyomin-X, induces tumor cell death by modulating genes related to the cell cycle and targeting the ubiquitin-proteasome system

The aim of this study was to evaluate the anti-tumor activity of Amblyomin-X, a serine protease Kunitz-type inhibitor. Amblyomin-X induced tumor mass regression and decreased number of metastatic events in a B16F10 murine melanoma model. Alterations on expression of several genes related to cell cycle were observed when two tumor cell lines were treated with Amblyomin-X. PSMB2, which encodes a proteasome subunit, was differentially expressed, in agreement to inhibition of proteasomal activity in both cell lines. In conclusion, our results indicate that Amblyomin-X selectively acts on tumor cells by inducing apoptotic cell death, possibly by targeting the ubiquitin-proteasome system.

Variability in expression of Bothrops insularis snake venom proteases: An ontogenetic approach

Bothrops insularis is a threatened snake endemic to Queimada Grande Island, southern coast of São Paulo, Brazil, and the occurrence of sexual abnormalities in males, females and intersexes (females with functional ovaries and rudimentary hemipenis) has been reported in this population. The aim of this study was to identify ontogenetic shifts in protease expression of offspring of captive-bred B. insularis. Three neonates from a single litter were maintained at the facilities of Laboratory of Herpetology, Institute Butantan, for 41 months. The snakes were individually milked and venoms were analyzed both by SDS-PAGE, under reducing conditions, and for biochemical activities. The venoms from the mother and from a pool of adult specimens were used as references. In regard to the electrophoretic patterns, common bands were identified mainly between 14 and 50 kDa among snakes. The occurrence of proteolytic activity was noticed predominantly between 27 and 45 kDa in zymograms. Inhibitory assays with 1,10-phenantroline (10 mM) and PMSF (5 mM) showed that venoms possessed both metalloproteases and serine proteases. Venoms of young specimens showed a higher coagulant activity than those of adults, especially upon factors X and II. All venoms presented fibrino(geno)lytic activity, degrading Aα and Bβ chains of fibrinogen, and lysing fibrin plate. These findings can reflect important individual, ontogenetic and sexual differences on venom composition and are likely correlated with diet habits of this species.

The snake venom metalloproteases berythractivase and jararhagin activate endothelial cells.

PIII snake venom metalloproteases (SVMPs) are metalloproteases structurally related to ADAMs (a disintegrin and metalloprotease human family of proteins). Berythractivase and jararhagin are PIII SVMPs with 69% homology that have different hemostatic properties. In order to clarify these differences and further characterize the biological effects of these proteins, we have analyzed the effect of both proteases on human umbilical-vein endothelial cell functions. We found that both proteins enhanced nitric oxide generation, prostacyclin production and interleukin-8 release. Berythractivase but not jararhagin increased the expression of decay accelerating factor. Jararhagin decreased cell viability in a concentration-dependent manner and induced cellular apoptosis, while berythractivase did not modulate cell survival. Our results show for the first time that, besides the known anti-aggregating or procoagulant effects of PIII SVMPs, these proteins trigger endothelial cell effector responses. Although structurally related, berythractivase and jararhagin induce a dissimilar generation and release of endothelial molecules that may account for their different hemorrhagic activity.